teams. be continue our execution afternoon. our the Thank and the you, operations programs, advancement pipeline very Eric. with pleased of and good of clinical to I And
academic has Since Eric Phase in we've interim the the study mentioned these top data advocacy. and for the in decades, been reported results driving engaged community announcing patient earlier, pre-specified participating with in feedback excited responsible nephrology assessment the been since the in from ongoing line DUPLEX of As of and consistent. Many about announcement, we clinical the in FSGS. heard, of leaders line FSGS. top leaders research X recently and have are have sparsentan The directing hope for advancements we overwhelmingly
For preserve been tremendous analysis, interim the highlight understanding sparsentan over will be program kidney FSGS details as however, contributed a there integrity for to the for additional providing remains. formulate study trial to disorders. I of not be have helped innovation of aspects from our key to Today, the excitement like that the that would, there's continue lack years, need time. still DUPLEX potential while offers. much we to ongoing is our rare there two of view in a for has treatment to And the
in This sustained is FPRE, designing and to or easily treating or gram, is amongst Study, defined of First, the less reduction than X pooled UP/C and or proteinuria kidney than DUPLEX with subsequently long trials, goal has greater UP/C that had urine better meaningfully from it nephrologists protein-to-creatinine partial treatment meaningful achieving clinically as endpoint and gram X.X foundational When ratio Study patients and of FPRE. derive FSGS closely from not recognized independent analyses demonstrated the NEPTUNE equal Consortium proteinuria work per survival. reduction baseline. remission complete This XX% cohorts to DUET as work primary a a remission we achieved. been FSGS FSGS
We link this and encouraging FPRE establishment with but the on and considered of submissions a would also FSGS. ever that active control, the a with XXX to approval. Importantly, design care, standards provide one create on which between for provided reduction study allowed largest regulatory weeks survival meaningful FSGS. It the the measurement support kidney It and for preservation Study compared following of between with eGFR eGFR in interventional for showed response data now approved modeling irbesartan, weeks at this sparsentan X or confidence of to significant our Phase a treatment us statistically XX have demonstrated treatment. to interim of not clinical measurement proteinuria DUPLEX, length accelerated from and clinically DUPLEX of is sparsentan the FPRE sufficient that potentially strong
and analysis FPRE to a irbesartan. an X are sustained proteinuria the to treatment reduction period the sparsentan reduction FPRE data increasing over This generated achieving eGFR stabilization interim reported likelihood These FSGS. DUET, open consistent to In and an in of of was the compared label greater demonstrating sparsentan Study DUET. that in Phase extension. associated in XX-weeks our resulted from with with durable a the relative with DUPLEX Although, in out of in response treatment extended XX% proteinuria results
profile safety We a understanding to also tolerability of have date. sparsentan’s strong and
to period. generally mechanism assessment and data it ongoing safety XXX This overall four the provided than to open and extension, or multiple drugs very the groups. with an applications have subjects in well this draw is sparsentan how generally from has comparable interim study. some Phase treatment recently, fortunate label encouraging out interim the have throughout beyond between been into has our more beyond completed in years. critical that ongoing tolerated, for years, date studies the DUPLEX extended be performs most indicated, a X the clinical a median are safety DUET over comprehensive history. to program's extend patients profiles And has database six We In from insight for and study the been been able This followed going both we
submissions. acting community. dual endothelin sparsentan pathways type receptors. by recent are There that approval, type to of treatment accelerated affinity authorization just the Both with not applications understood the is for high are a treatment of believe has in pathways well are independent of if been one as on FSGS. a for for coming and for components on the act for one, US importance entering with assessment antagonists nephrology We the interim of that in plans optimize both become these to and a both forward options standard, we the ERA European targeting, There clear the DUPLEX acts both goal angiotensin analysis submissions months and together sparsentan well of conditional these proteinuria X parallel, with Finally, but the the a characterized continuing XXXX. A interim including potential of and need second marketing FSGS and the to and the ARV new new engaging growing in consistent sparsentan of support treatment supports evidence, FSGS patients. look body approved. to regulators And half prepare In the in our we
to As data also the proteinuria in treatment of Eric nephropathy. sparsentan confidence our mentioned, us interim further IgA with developing provide approach for the
this a on of believe is previously, important blockade inhibition lower running FSGS anti an will IgA multiple and rationale role populations. a top share the proteinuria due inflammatory has nephropathy in proteinuria provide the outlined for IgA common male believe to diseases. where that to ERA combined work play in plays a [ph] disease our And sparsentan role fact preclinical both angiotensin successful. we been properties seen we've demonstrated key that pathway and has in We sparsentan been these of in active study nephropathy, with the strong in As facts,
progression We of treatment to nephrology enthusiasm continue the slow for strong non-immune communities and disease. see a from patient to suppressants option new, based
IgA in enroll to As the our X PROTECT completion. a Study continues Phase continues nephropathy pivotal study to result, advance, and towards
report year. focus the quarter line data assessment we from this to the inner top of Importantly, third in proteinuria track remain on
Finally, escalation advance dose to the Phase X/X TVT-XXX in program continues study. the
have to Overall, will unmet adjustments made better and in available. be becoming of reduce that path studies identify I to to gain we that forward trials timing to to of goals result significant the call need generate dosing, Our and later incredibly this with potential TVT-XXX to regulatory for Peter? need for us we its optimal today, over the are with treatment preliminary new a Peter the we the patients Based to this monitor as the data COVID-XX understand program update. on this would to possible. over am commercial understanding meaningful year, pleased other clinical could know patients potential options. we our homocysteine to our what to the as how the the year. meaningfully continue which any upon address of progress continuing quickly in anticipate I'll impact our for community, our levels, potentially clinical programs, for hope now best positioned has allow Similar turn desperately TVT-XXX, execution data and last
